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Abstract The effect of the novel, naturally occurring nucleotide
cyclic diguanylic acid (c-di-GMP) on the lymphoblastoid CD4+
Jurkat cell line was studied. When exposed to 50 WM c-di-GMP,
Jurkat cells exhibited a markedly elevated expression of the CD4
receptor of up to 6.3-fold over controls. C-di-GMP also causes
blockage of the cell cycle at the S-phase, characterized by
increased cellular thymidine uptake, reduction in G2/M-phase
cells, increase in S-phase cells and decreased cell division.
Additionally c-di-GMP naturally enters these cells and binds
irreversibly to the P21ras protein. The effects described appear to
be unique for c-di-GMP.
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1. Introduction
3P,5P-Cyclic diguanylic acid (c-di-GMP) (Fig. 1a) is a novel
cyclic regulatory nucleotide which has been identi¢ed in pro-
karyotic systems and found to be active also in eukaryotic
systems [1]. Our study [2] was the ¢rst report on the e¡ects
of this nucleotide in a mammalian system: the Molt 4 lym-
phoblastoid cell line. C-di-GMP was found to dramatically
increase cellular thymidine incorporation into Molt 4 cells
and, correspondingly, to elevate DNA levels in treated cells
but not cell replication. Within the Molt 4 cell, c-di-GMP
speci¢cally binds to the p21ras protein, apparently in an irre-
versible fashion, thereby maintaining it in a ¢xed active con-
formation.
The function of Ras in the control of cell fate decision was
studied extensively. Ras has been shown to be involved in
signaling the di¡erentiation of T-lineage cells and to induce
the expression of the T-cell receptors, CD4 and CD8 [3]. Since
c-di-GMP activates Ras in Molt 4 cells [2], we sought ¢rst to
determine whether this unique nucleotide can speci¢cally bind
to the p21ras protein in Jurkat cells and secondly whether
treatment with c-di-GMP a¡ects the T-cell receptor, CD4 in
these cells. For this purpose, we studied the e¡ects of c-di-
GMP on this CD4-bearing lymphoblastoid cell line.
In this paper, we report that following its natural entrance
into Jurkat cells, c-di-GMP speci¢cally and irreversibly binds
to the growth-promoting protein p21ras ; that c-di-GMP treat-
ment causes a markedly elevated expression of the CD4 re-
ceptor in these cells and that c-di-GMP-treated cells exhibit
properties compatible with those of S-phase-arrested cultures.
Taken together, we feel that the novel nucleotide c-di-GMP
might o¡er a potentially powerful tool for studying signals
involved in T-cell regulation.
2. Materials and methods
2.1. Materials
GTP[S] and a⁄nity absorbent glutardialdehyde-activated beads
were purchased from Boehringer, Mannheim, Germany; cyclic
GMP, GDP, GMP, p[NH]ppG, GTP, di-isopropyl £uorophosphate
(DFP), PMSF, aprotinin, sodium orthovanadate, leupeptin and rabbit
anti-rat IgG were from Sigma Chemicals Co. (St. Louis, MO, USA);
thin-layer plates of polyethyleneimine (PEI)-cellulose were from
Machery Nagel (polygram Cell 300 PEI); rat anti-p21ras monoclonal
antibody Y13-259 was from Santa Cruz Biotechnology; rat anti-
mouse IgG monoclonal antibody was purchased from Caltag Labo-
ratories (San Francisco, CA, USA). C-di-GMP and [32P]c-di-GMP
were synthesized as in [2]. [K-32P]GTP was from Amersham (UK)
and [3H]methyl-thymidine from NRC (Negev, Israel).
2.2. Cell lines
Jurkat cells were grown at 37‡C in RPMI 1640 medium supple-
mented with 10% (v/v) heat-inactivated fetal calf serum (Biological
Industries, Kibbutz Bet Ha’emek, Israel) as described previously [2].
2.3. [3H]Methyl-thymidine incorporation
Jurkat cells were incubated in 96-well culture plates in the presence
of various nucleotides for 24 and 48 h. Cells were then exposed to
[3H]thymidine, 1.0 WCi per well, for an additional 4 h. The label
content in trichloroacetic acid-precipitable material obtained from
the cultures was quanti¢ed by liquid scintillation counting.
2.4. Entrance of c-di-GMP to Jurkat cells
Jurkat cells, 2.5U105, were grown at 37‡C in the presence of 50 WM
[32P]c-di-GMP (0.5 mCi/Wmol) per well in 96-well tissue culture plates.
After 24 h, cells were collected by centrifugation, washed and nucleo-
tides extracted as described [2]. Two-dimensional TLC for resolution
of nucleotides was done on PEI-cellulose plates, using 1.5 M
KH2PO4, pH 3.65 (solvent A) for the ¢rst dimension and 0.75 M
Tris/0.45 M HCl/0.5 M LiCl (solvent B) for the second dimension.
Other solvents used were: 0.2 M NH4HCO3 (solvent C), 0.2 M
(NH4)2CO3 (solvent D) and 5.5 M (NH4)2SO4, pH 3.5 (solvent E).
Labelled compounds were detected by autoradiography and quanti-
¢ed as in [2].
2.5. Immunoprecipitation
Jurkat cells were incubated at 37‡C for 24 h in the presence of 5 mM
[32P]c-di-GMP (0.8 Ci/Wmol) or 10 mM [K-32P]GTP (0.8 Ci/Wmol).
The cells were removed from the plates, washed three times and lysed
as described previously [2]. Post-nuclear supernatants were immuno-
precipitated by rotating for 40 min at 4‡C using anti-p21ras monoclo-
nal Y13-259 antibody pre-coupled to a⁄nity absorbent glutardialde-
hyde-activated beads by rabbit anti-rat IgG. All immunoprecipitations
were carried out in duplicate and rat anti-mouse IgG monoclonal
antibody was used as control. Immunoprecipitates were washed six
times with lysis bu¡er [2] and bound proteins were eluted by boiling in
50 Wl of electrophoresis sample bu¡er for 5 min, followed by SDS-
PAGE analysis and autoradiography [2].
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2.6. Enzymatic assay of c-di-GMP
The enzymic assay of c-di-GMP, which is based on the highly c-di-
GMP-speci¢c activation of the cellulose synthase of Acetobacter xyli-
num, was employed [4]. The concentration of c-di-GMP in samples
was calculated as previously described [5].
2.7. Immuno£uorescent staining and £ow cytometric analysis
Cells were stained with antibodies following standard procedures.
The following antibodies were used: anti-CD4 leu3A and anti-CD8
leu2A (Becton-Dickinson, San Jose, CA, USA) and £uorescing iso-
thiocyanate (FITC) conjugated rabbit anti-mouse IgG (Zymed, San
Francisco, CA, USA). DNA content was analyzed by propidium io-
dide staining of ¢xed cells following standard procedures. All analyses
were carried out using a FACScan £ow cytometer (Becton-Dickinson,
San Jose, CA, USA).
2.8. Immunoblotting
Jurkat cells were lysed in RIPA lysis solution (0.15 mM NaCl/0.05
mM Tris-HCl, pH 7.2/1% Triton X-100/1% sodium deoxycholate/
0.1% SDS) at 108 cells/ml, and postnuclear supernatants were pre-
pared following standard procedures. Proteins were resolved by
SDS/10% PAGE (with 2U106 cell equivalents of lysate loaded per
lane), transferred onto Immobilon-P membranes (Millipore), and
blotted with anti-p56lck rabbit polyclonal antiserum followed by al-
kaline phosphatase-conjugated goat anti-rabbit IgG (Southern Bio-
technology Associates). Color reaction was developed with the
BCIP/NBT substrate kit for alkaline phosphatase (Zymed).
3. Results
3.1. Entrance of c-di-GMP into Jurkat cells
To study possible c-di-GMP e¡ects on the T-cell receptor,
CD4 in the Jurkat cell line, the entrance of c-di-GMP into the
cells was ¢rst ascertained. Nucleotides extracted from Jurkat
cells, grown in the presence of [32P]c-di-GMP, and then ex-
tensively washed, were analyzed for the presence of labelled c-
di-GMP by two-dimensional TLC (using solvents A and B)
and autoradiography. Fig. 1b shows the autoradiogram ob-
tained, revealing a well-resolved spot which co-migrated with
a similarly chromatographed [32P]c-di-GMP marker. Extracts
of the spot were subjected to further TLC analysis in various
solvent systems. In all cases a single spot exhibiting the dis-
tinct mobility of c-di-GMP was detected with Rf values of
0.19, 0.35 and 0.03 in solvents C, D and E, respectively. Sim-
ilar analysis of the last washing of the cells, as well as extracts
of pre-heat-inactivated cells, showed no traces of c-di-GMP.
The occurrence of c-di-GMP in the cell extracts described was
further established by the ability of extracts derived from un-
labelled c-di-GMP-treated cells to activate the c-di-GMP-spe-
ci¢c cellulose synthase of Acetobacter xylinum [4,5]. These
experiments strongly suggest that c-di-GMP enters Jurkat
cells. The concentration of free intracellular c-di-GMP was
found to reach a value of 35 pmol/106 cells, as determined
by both TLC and enzymic analysis [5]. This value represents
the mean from at least four independent analyses for each
method. S.E.M. values were always less than 10% of the
mean. Results were statistically signi¢cant at P6 0.001.
3.2. C-di-GMP speci¢cally binds to P21ras in Jurkat cells
To determine whether c-di-GMP binds to p21ras in the
CD4+ cell line, Jurkat cells previously incubated for 24 h
with either [32P]c-di-GMP or [K-32P]GTP were lysed and
then immunoprecipitated with the anti-Ras monoclonal anti-
body Y13-259. The precipitates were subjected to SDS-PAGE
analysis and autoradiography. As seen in Fig. 2, lanes 1 and
2, a labelled band of 21 kDa was observed in both immuno-
precipitates. Notably, the label intensity of the band derived
from c-di-GMP-treated cells is considerably higher than that
derived from GTP-treated cells, in spite of the relatively lower
molar concentration of the c-di-GMP employed. This band
was not seen when Y13-259 was substituted with rat anti-
mouse IgG monoclonal antibody (lanes 7 and 8). Labelling
by [32P]c-di-GMP was not signi¢cantly a¡ected (less than 5%
as analyzed by scanning densitometry) in the presence of un-
labelled GTP, GDP and GMP at 1000-fold molar excess
(lanes 3, 4 and 5). In contrast, unlabelled c-di-GMP, at
1000-fold molar excess, entirely blocked this labelling (lane
6). The results of those competition experiments suggest that
c-di-GMP itself binds to p21ras, rather than a guanosine phos-
phate which may be generated from the cyclic dinucleotide.
This conclusion is compatible with the demonstrated presence
of c-di-GMP within cells incubated with the dinucleotide. It is
noteworthy that unlabelled c-di-GMP at 1000-fold molar ex-
cess did not signi¢cantly a¡ect the labelling by [K-32P]GTP
(less than 5% as analyzed by scanning densitometry) (data
not shown). This could imply that c-di-GMP may bind to a
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Fig. 1. Structural formula of c-di-GMP and two-dimensional TLC
of extracts of [32P]c-di-GMP-grown Jurkat cells. a: Structural for-
mula of c-di-GMP. b: Extracts of Jurkat cells grown in the presence
of [32P]c-di-GMP were chromatographed in solvent A in the ¢rst di-
mension and in solvent B in the second dimension, as described in
Section 2. Presented is an autoradiogram of the exposed TLC plate.
The large dark spot coincides with the position of a similarly chro-
matographed [32P]c-di-GMP marker.
Fig. 2. SDS-PAGE analysis of immunoprecipitates of p21ras from
lysates of Jurkat cells labelled with [32P]c-di-GMP or [K-32P]GTP.
Jurkat cells were incubated with either 5 nM [32P]c-di-GMP (0.8 Ci/
Wmol; lanes 1, 3^6, 8) or 10 nM [K-32P]GTP (0.8 Ci/Wmol; lanes 2
and 7) in the absence of additional unlabelled nucleotides (lanes 1,
2, 7, 8) or in the presence of either 5 WM c-di-GMP (lane 6), 5 WM
GTP (lane 3), 5 WM GDP (lane 4) or 5 WM GMP (lane 5). Cells
were lysed and immunoprecipitated as described in Section 2 with
the following antibodies: lanes 1^6: Ras-speci¢c monoclonal anti-
body Y13-259; lanes 7 and 8: rat anti-mouse IgG monoclonal anti-
body. 10 WM unlabelled c-di-GMP had no e¡ect on [K-32P]GTP la-
belling.
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non-nucleotide-speci¢c region of p21ras, a conclusion compat-
ible with the observed inability of the various guanine nucleo-
tides to inhibit the interaction between c-di-GMP and RAS.
3.3. C-di-GMP speci¢cally elevates CD4 expression in Jurkat
cells
The results in Fig. 3C show that when incubated with Jur-
kat cells c-di-GMP at 50 WM induces a 6.3-fold upregulation
of CD4 over control (52.44% CD4-positive cells versus 8.32).
The e¡ect was dose-dependent and treatment with 100 WM
c-di-GMP resulted in a 9.1-fold increase over control (data
not shown). The c-di-GMP-induced upregulation of CD4
was speci¢c and was not observed with c-GMP or GTP,
nor with the unhydrolyzable GTP analogues, GTP[S] and
p[NH]ppG, at concentrations up to 100 WM. C-di-GMP af-
fected only CD4 expression, but had no e¡ect on the expres-
sion of CD8 (data not shown).
3.4. CD4 elevated expression is not accompanied by a
commensurate increase in p56lck
Since CD4-derived signals are transduced into the cell by
associated tyrosine kinase p56lck molecules [11,12], we sought
to ¢nd out whether the amount of lck in c-di-GMP-treated
cells was correspondingly elevated. For this purpose, 24 h c-
di-GMP-treated Jurkat cells lysates were immunoblotted with
anti-lck antibody and, as revealed in Fig. 3D, lck levels were
not signi¢cantly increased over control (less than 4% as quan-
ti¢ed by scanning densitometry).
3.5. E¡ects of c-di-GMP on [3H]thymidine incorporation into
Jurkat cells
C-di-GMP has been shown to dramatically increase
[3H]thymidine incorporation (up to 200-fold of control) into
Molt 4 cells [2]. As seen in Table 1, when incubated for 24 h
with Jurkat cells, c-di-GMP at a concentration of 50 WM
caused a 43-fold increase in thymidine incorporation into
the cells. Fold stimulation over control samples increased fur-
ther at 100 WM c-di-GMP and following incubations for 48 h.
This marked e¡ect was not observed with c-GMP, GMP or
GTP (Table 1), nor with the unhydrolyzable guanine nucleo-
tides, GTP[S] and p[NH]ppG, which at concentrations up to
100 WM did not a¡ect [3H]thymidine uptake (results not
shown). On the other hand, c-di-GMP had a negative e¡ect
on cell replication since the number of treated cells did not
increase signi¢cantly after 24 and 48 h of incubation, as com-
pared to that observed in control cultures which increased by
44 and 90%, respectively.
3.6. Cell cycle arrest in c-di-GMP-treated cells
Since cells treated with c-di-GMP exhibit a dramatic in-
crease in [3H]thymidine incorporation, we further character-
ized the state of c-di-GMP-treated cells by £ow cytometry
(Fig. 3A). When cells were treated with 50 WM c-di-GMP
for 24 h, the percentage of cells in S-phase increased by
79%, with almost complete disappearance of G2/M-phase cells
which decreased by 93%. These results suggest that c-di-GMP
may cause a blockage of the cell cycle at the S-phase. C-di-
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Fig. 3. E¡ect of c-di-GMP on cell cycle, light scattering behavior
and CD4 and lck expression in Jurkat cells. Jurkat cells were un-
treated (control) or treated with 50 WM c-di-GMP for 24 h (A, B).
Cells were ¢xed with ethanol, stained with propidium iodide and
analyzed by £ow cytometry. A: Plot of cell number against DNA
content. B: Right angle light scatter histogram. C: Cells were har-
vested and analyzed for CD4 expression by £ow cytometry as de-
scribed in Section 2. The left peaks represent analyses of control
cells without ¢rst antiserum. The vertical line indicates the position
of control staining. The ¢lled area represents CD4-positive cells and
values denote percent CD4-positive cells. D: Cells lysates were re-
solved in SDS-10% PAGE and immunoblotted with an anti-lck anti-
serum, as described in Section 2. Samples shown are in duplicate.
Data presented in A, B, C and D represent one of at least three in-
dependent experiments, each performed in duplicate. Results similar
to control were obtained when cGMP or GTP were used in the dif-
ferent assays.
Table 1
E¡ects of c-di-GMP concentration on [3H]thymidine incorporation
into Jurkat cells with time
Addition [3H]-Thymidine incorporation (cpm U103)
24 h 48 h
^ 1.5 2.4
50 WM c-di-GMP 65 160.8
50 WM c-GMP 2.4 2.4
50 WM GMP 2.2 2.4
50 WM GTP 2.7 2.6
100 WM c-di-GMP 97.5 192
Jurkat cells were incubated for 24 and 48 h in the absence or presence
of the various guanine nucleotides, at concentrations of 50 and
100 WM for c-di-GMP and 50 WM for c-GMP and GTP, then pulsed
with [3H]thymidine and assayed as described in Section 2. Values
represent means from at least three independent experiments, each
performed in triplicate. S.E.M. was always less than 10% of the
mean. P6 0.001.
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GMP treatment did not increase the rate of cell death relative
to that in control cultures, since the amount of fragmented
DNA did not increase in treated cells. This was veri¢ed when
cell death was evaluated by trypan blue exclusion. Notably, in
these experiments too, total cell number in c-di-GMP-treated
cultures did not signi¢cantly increase as assessed by cell
counting. Thus, although c-di-GMP-treated cultures exhibited
a high percentage of S-phase cells, overall cell replication was
drastically impaired.
Light scattering properties of cells are dependent on cell
size. In a randomly proliferating cell population, the larger
cells in the G2/M-phase have increased forward and right
angle light scatter values compared with their smaller counter-
parts in G1 phase [6]. Light scatter analyses of c-di-GMP-
treated cells revealed a signi¢cant shift in population cell
size, showing decreased forward (data not shown) and right
angle light scatter values compared with controls (Fig. 3B),
indicating cells to be of a smaller size. The c-di-GMP e¡ects
on cell size and cell type distribution were speci¢c and were
not observed in cells treated with c-GMP, GTP[S], p[NH]ppG
or GTP at 50 WM for 24 h.
4. Discussion
This study reports on the speci¢c binding of the unique,
naturally occurring regulatory nucleotide c-di-GMP to the
P21ras protein and its ability to stimulate expression of the
CD4 receptor in the CD4+ Jurkat cell line. Ras is known to
be involved in signaling the di¡erentiation of T-linkage cells
[7,8], and in its activated form has been shown to cause tran-
sition of double negative (DN) prothymocytes to double pos-
itive (DP) thymocytes, thus inducing the expression of the T-
cell receptors CD4 and CD8 [3]. C-di-GMP was demonstrated
to freely enter Jurkat cells (Fig. 1b) and was found to bind to
the P21ras protein. Since this binding is apparently speci¢c and
cannot be blocked by other guanine nucleotides (Fig. 2), and
since it remains attached to P21ras after boiling, suggesting
that they are covalently linked, it appears that the cyclic nu-
cleotide binds irreversibly to P21ras, apparently in the non-
nucleotide-speci¢c region of RAS, and possibly maintaining
it in a ¢xed conformation. Since the upregulation of the CD4
receptor observed in c-di-GMP-treated cells appear to be
unique to c-di-GMP it is tempting to speculate that the irre-
versible binding of c-di-GMP with p21ras may result in a com-
plex that possibly maintains the protein in a ¢xed active form,
which in turn may relate to the markedly induced overexpres-
sion of CD4 in c-di-GMP-treated cells. Introduction of a con-
stitutively activated Ras expression construct was reported to
be su⁄cient to induce the transition from DN prothymocytes
to the DP stage [3], the expression of activated Ras was not
su⁄cient to induce negative selection and maturation towards
a single positive form, either CD4 or CD8. In our case, c-di-
GMP treatment of single positive Jurkat cells speci¢cally in-
duced CD4 expression (6.3-fold over controls) but did not
a¡ect expression of the CD8 receptor. Considering other re-
ports on elevated expression of the CD4 receptor using thy-
mocytes from CD4 transgenic mice [9] and CD4-transfected
human T-cells [10], we obtained our e¡ect by exposing Jurkat
cells to the novel cyclic nucleotide, and it should be noted that
c-di-GMP-treated cells were not genetically altered and the
e¡ects described here were observed under conditions which
we feel avoid perturbation of cell genetic regulation.
CD4-mediated T-cell activation is trans-signalled through
the lymphoid-speci¢c tyrosine kinase p56lck [11]. To assist
receptor-mediated antigen recognition, p56lck associates
physically and functionally with the CD4 receptor [12]. It
would thus be reasonable to expect that increased expression
of the CD4 receptor would cause a concomitant elevation in
the level of its intracellular signaling counterpart p56lck.
However, our experiments show that the excessive upregula-
tion of CD4 in c-di-GMP-treated cells was not accompanied
by a commensurate increase in associated p56lck. In this re-
spect our results are in accord with the overexpression of CD4
in mouse T-cells which similarly did not result in a propor-
tionate increase in p56lck molecules [9].
We have previously shown that c-di-GMP exerts an unusu-
al e¡ect on the cell cycle of Molt 4 lymphoblasts, causing
them to enter the S-phase uncoordinated with their overall
replication rate [2]. Flow cytometric analysis of c-di-GMP-
treated Jurkat cells (Fig. 3A) revealed that the percentage of
cells in the S-phase increased by 79%. Concomitantly there
was a slight fall in the proportion of cells in the G1-phase
with an almost complete disappearance of G2/M-phase cells.
While the occurrence of a high percentage of c-di-GMP-
treated cells in the S-phase is consistent with their elevated
uptake of thymidine (Table 1), these e¡ects were, surprisingly,
not accompanied by an expected corresponding increase in
cell division but rather in cessation of cell proliferation, which
taken together strongly suggest that an S-phase arrest is in-
duced in Jurkat cells by c-di-GMP.
Cell size is a critical parameter in the mechanisms which
control cellular proliferation in the yeast system [13], and a
reduced cell size can be obtained when overexpression of
mammalian cyclins, such as D1 and E, occurs [13]. Light
scatter analysis of c-di-GMP-treated cells (Fig. 3B) revealed
a signi¢cant shift in population cell size, indicating cells to be
of a smaller size, which is compatible with such cells being
mostly in G1- and S-phases where cells are usually of smaller
size. Considering these ¢ndings and the dramatic increase in
cellular thymidine uptake accompanied by blockage of cell
proliferation, it appears that although c-di-GMP-treated cells
could enter S-phase and augment their DNA content, they
could not complete S-phase and undergo mitosis. It is note-
worthy that c-di-GMP-treated Jurkat cells were grown in 10%
fetal calf serum-containing medium, providing optimal condi-
tions for cell growth and proliferation, thereby avoiding the
deleterious e¡ect on cell fragility, viability, growth rate and
metabolism, reportedly associated with changes in medium
serum levels [14].
It is believed that activated Ras plays an important role in
the growth and cell size regulation of mammalian cells. In-
troducing activated Ras into Schwann cells or rat embryo
¢broblasts has been reported to result in arrest of growth
[15,16], and inhibition of proliferation was observed when
PC12 cells were microinjected with Ras protein [17].It may
be suggested that the S-phase arrest apparently induced by
c-di-GMP in Jurkat cells could be related to the irreversible
binding of c-di-GMP to P21ras, which possibly maintains the
proto-oncogenic protein in a ¢xed active state.
Taking all the data presented here into consideration, we
feel that our experimental system, using the naturally occur-
ring guanine nucleotide c-di-GMP, might o¡er a potentially
powerful means of studying signals involved in the control of
cell fate decision in lymphocytes.
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